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Abstract
Krüppel-like factor 4 (KLF4) is a zinc finger transcription factor that functions as an oncogene or tumor suppressor
in a highly tissue-specific cell-dependent manner. However, its precise role in breast cancer and metastasis re-
mains unclear. Here, we show that transient adenoviral expression of KLF4 in the 4T1 orthotopic mammary cancer
model significantly attenuated primary tumor growth as well as micrometastases to the lungs and liver. These re-
sults can be attributed, in part, to decreased proliferation and increased apoptosis. Further supporting a tumor-
suppressive role for KLF4 in the breast, we found that KLF4 expression is lost in a mouse model of HER2/NEU/
ERBB2–positive breast cancer. To determine whether enforced KLF4 expression could alter tumor latency in these
mice, we used a doxycycline-inducible expression model in the context of the MMTV-Neu transgene. Surprisingly,
tumors that developed in this model also lost KLF4 expression, suggesting negative selection for sustained expres-
sion. We have previously reported that KLF4 inhibits epithelial-to-mesenchymal transition (EMT), a preliminary step
in metastatic progression. Overexpression of KLF4 in 4T1 cells led to a significant reduction in the expression of
Snail, a key mediator of EMT and metastasis. Conversely, KLF4 silencing increased Snail expression in the non-
transformed MCF-10A cell line. Collectively, these data demonstrate the first functional, in vivo evidence for KLF4
as a tumor suppressor in breast cancer cells. Furthermore, our findings suggest an inhibitory role for KLF4 during
breast cancer metastases that functions, in part, through repression of Snail.
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Introduction
Krüppel-like factor 4 (KLF4) is a zinc-finger transcription factor that
regulates a multitude of processes in normal tissue including prolifer-
ation, differentiation, apoptosis, tissue homeostasis, and self-renewal
[1–5], to name a few. KLF4 can also have both tumor-suppressive
and oncogenic roles in cancer. KLF4 was first identified as a tumor
suppressor, owing to frequent loss of expression in colon, esophageal,
gastric, bladder, prostate, and lung cancers [6–11]. Subsequent stud-
ies, however, have suggested a role for KLF4 as an oncogene in other
tissues, including breast [12,13]. Paradoxically, KLF4 was most re-
cently found to suppress estrogen-dependent breast cancer cell growth,
and its expression is inversely correlated with increasing tumor stage
and grade [14], further confounding its role in this disease.
In human mammary epithelial cells, KLF4 is a transcriptional acti-
vator of E-cadherin and suppressor of epithelial-to-mesenchymal tran-
sition (EMT) [15]. This process, whereby cells acquire a fibroblast-like
morphology and altered molecular signature associated with reduced
cellular adhesion and increased motility, is critical not only during de-
velopment but may also be involved in cancer progression [16,17].
While controversy still persists over the existence of EMT during tu-
morigenesis and metastasis, compelling evidence supporting its rele-
vance in human carcinomas, including breast, prostate, melanoma,
and others, has been reported (see review of Blick et al. [18]). A hall-
mark of EMT is the loss of E-cadherin expression, which is tran-
scriptionally suppressed by Snail [19]. In breast cancer, both loss of
E-cadherin and increased Snail expression are predictive of poor prog-
nosis [20]. Furthermore, Snail correlates with increasing tumor grade,
lymph node status, and metastasis [21].
Disease recurrence and distant metastases are the leading cause
of death in breast cancer patients. One subtype of breast cancer that
is highly metastatic involves the amplification and overexpression of
the HER2/Neu gene in 15% to 30% of all breast cancer cases. Ele-
vated expression of this receptor tyrosine kinase is associated with a
higher risk of recurrence because tumors that are initially responsive
to trastuzumab (Herceptin) often become resistant. One mechanism
by which HER2/Neu–dependent tumors can recur is through up-
regulation of Snail [22]. However, the mechanisms by which Snail
is induced are not well understood. Here, we demonstrate that forced
expression of KLF4 in the clinically relevant, orthotopic 4T1 xenograft
model inhibits primary tumor growth and metastases. We also show
that KLF4 expression is suppressed in a mouse model of HER2/Neu–
induced tumorigenesis. Furthermore, in vitro analyses revealed that
KLF4 is able to suppress Snail expression, suggesting a mechanism
whereby loss of KLF4 leads to increased breast cancer metastasis.
Materials and Methods
Transgenic Mice
All mice were housed in microisolator-plus units under pathogen-free
conditions in a 12-hour light-dark cycle. Food and water were provided
ad libitum. The NeuN mice (FVB/N-TgN(MMTV-neu)202Mul),
containing the rat proto-oncogene c-neu transgene [23], and the NeuT
mice (FVB/N-Tg(MMTV-Erbb2)NK1Mul/J), containing the activated
c-neu transgene [24], both targeted to mammary epithelium by the
MMTV-LTR promoter, were purchased from Jackson Laboratories
(Bar Harbor, ME). The TRE-KLF4 and MMTV-rtTA (MTB) mice,
both on the FVB/N genetic background, have been previously char-
acterized [3,25]. Mice were killed once initial tumors had reached
1.5 cm by caliper measurement. All animal studies were approved by
the Case Western Reserve University Institutional Animal Care and
Use Committee.
Microarray and Expression Analyses
Microarray analyses comparing age-matched wild-type glands
(AMWT), hyperplastic tissue adjacent to the tumor, and NeuN tu-
mors has been described in detail [26]. Quantitative real-time poly-
merase chain reaction (qRT-PCR) was performed on RNA harvested
from tissue and cells as previously described [15,26] using mouse and
human gene–specific TaqMan assays (Applied Biosystems, Carlsbad,
CA). RNA levels were normalized against mouse Gapdh, mouse
β-actin, or human TATA box binding protein (TBP) as indicated.
Cell Culture and Generation of 4T1-Luciferase Cells
The MCF-10A and 4T1 cells lines were purchased from ATCC
(Manassas, VA). Generation and characterization of MCF-10A cells
with stable knockdown of KLF4 (shKLF4) have been reported [15].
The MCF-10A and 4T1 progression series were obtained fromDr Fred
Miller at Karmanos Cancer Institute. All MCF-10A lines, including
the MCF-10AT1K, MCF-10CA1h, and MCF-10CA1a, were cultured
in complete medium [27]. All 4T1 lines, including the 67NR and the
4T07, were cultured in Dulbecco modified Eagle medium (Mediatech,
Inc, Manassas, VA) supplemented with 10% fetal bovine serum and
1% penicillin-streptomycin.
4T1-luciferase–expressing cells (4T1-luc) were generated by subclon-
ing the complete gene from the Luciferase T7 Control DNA (Promega,
Madison, WI), as a BamHI/SacI fragment into pBlueLZRS-2. Subse-
quent digestion yielded the luciferase containing BamH1/SfiI frag-
ment, which was inserted into the LZBOB-Hygro retroviral expression
vector. Virus was generated using the Phoenix packaging cells as de-
scribed [28], with modifications. (Vectors and Phoenix cells were kind
gifts from Keith R. Johnson, University of Nebraska Medical Center).
Briefly, transfected Phoenix cells were cultured for 48 hours at 37°C
before virus-containing medium was harvested. 4T1 cells were plated
overnight at a low density and infected the next day with 0.45-μm fil-
tered virus-containing medium, supplemented with 4 mg/ml polybrene
(Sigma, St Louis, MO). The medium was changed after overnight in-
cubation at 32°C. Infected 4T1 cells were cultured to 80% confluency
and selected in 100 μg/ml hygromycin (Invitrogen, Carlsbad, CA).
Transwell Migration and Invasion Assays
Assays were performed as previously described [15]. Briefly, 5.0 ×
105 cells were seeded onto transwell supports (Costar, Corning, NY)
or BD Matrigel Invasion Chambers (BD Biosciences, Bedford, MA)
and allowed to migrate or invade toward complete medium for the
indicated times. Five (20×) fields per transwell support were counted.
Bromodeoxyuridine Incorporation and Fluorescence-Activated
Cell Sorting Analysis
4T1 cells were infected with empty vector adenovirus control
(AdGFP) or KLF4-expressing adenovirus (AdKLF4) [15] for 72 hours
before a 30-minute incubation with 10 μMbromodeoxyuridine (BrdU;
Sigma-Aldrich) at 37°C. Cells were fixed and labeled with anti-BrdU
(BD Biosciences) and analyzed by fluorescence-activated cell sorting
(FACS) as previously described [15].
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4T1 Orthotopic Tumor Model
Twenty-four hours before injection, 4T1 or 4T1-luc cells were
infected with AdGFP control or AdKFL4. The next day, cells were
trypsinized, washed, and counted before resuspension in Dulbecco
modified Eagle medium. Female BALB/c mice (Jackson Laboratories),
6 to 8 weeks old, were inoculated with 0.5 × 106 cells (50 μl) in a
no. 9 mammary fat pad. Tumors were measured weekly by calipers.
Mice injected with luciferase-expressing cells were anesthetized with
2% isoflurane and injected intraperitoneally with 200 μl of D-luciferin
potassium salt at 12.5 mg/ml in phosphate-buffered saline 5 minutes
before imaging on a Xenogen IVIS 200 scanner (Caliper Sciences,
Hopkinton, MA).
Morphologic and Immunohistochemical Analysis
Tissues were fixed overnight in 4% paraformaldehyde and embed-
ded in paraffin. Five-micrometer sections were dewaxed and stained
with hematoxylin and eosin. For immunostaining, cleared sections
were rehydrated, and antigen retrieval was performed using 10 mM
sodium citrate buffer (pH 6.0) in a pressure cooker for 20 minutes
at 125°C. Endogenous peroxidases were quenched in block (Dako
EnVision+ System-HRP; Dako, Carpinteria, CA) containing 15 μl/ml
normal goat serum (Jackson Immunologicals, West Grove, PA), and sec-
tions were incubated overnight at 4°C with primary antibodies: anti-
KLF4 (1:500, H-180; Santa Cruz Biotechnology, Santa Cruz, CA),
anti-Flag (1:500, M2; Sigma), or anti–cytokeratin 5/6 (1:20; Zymed,
Heidelberg, Germany). Slides were washed in Tris-buffered saline–
0.05% Tween 20 and incubated with labeled polymer–horseraddish
peroxidase antirabbit or antimouse (Dako) for 1 hour at room tem-
perature. The signal was developed using 3,3′-diaminobenzidine, and
slides were counterstained with hematoxylin and mounted. Images
were captured using a Nikon microscope (Nikon Instruments, Inc,
Melville, NY) and Zeiss AxioCam HRc imaging system (Carl Zeiss
MicroImaging, LLC, Thornwood, NY).
Identification of Lung and Liver Metastases
Lung metastases were identified by in vivo bioluminescence imag-
ing or hematoxylin and eosin–stained sections. Six sections per lung,
collected at 100-μm intervals, were evaluated. Two liver sections per
mouse, separated by at least 100 μm were stained with cytokeratin 5/6
and counted to quantify tumor cell infiltrate and micrometastases.
Western Blot Analysis
Cells were lysed in radioimmunoprecipitation assay buffer as pre-
viously described [15], and 50 μg of whole-cell lysates was sepa-
rated on 12% SDS-PAGE. Western blots were probed with primary
Figure 1. KLF4 expression is low in breast cancer cell lines compared with nontransformed mammary epithelial cell lines and inversely
correlates with metastatic progression. (A) Western blot and densitometric quantification comparing KLF4 expression among nontrans-
formed MCF-10A and MCF-12A mammary epithelial cells and breast cancer cell lines. qRT-PCR analysis of the (B) MCF-10A and (C) 4T1
progression series reveals decreasing KLF4 expression with increasing tumorigenicity and/or metastatic capacity. Protein or total RNA
was harvested from cells at 60% to 70% confluency. (D) Transwell migration of 4T1 cells is inhibited by KLF4. (E) KLF4 inhibits 4T1 cell
invasion into the Matrigel. Cells were allowed to migrate or invade, toward complete medium for 6 and 24 hours, respectively. Experi-
ments were performed at least three times in triplicate. *P < .01. **P < .001. ***P < 5.0e − 4. #P < 1.0e − 4. Overexpression of KLF4
in cells used for migration and invasion experiments is confirmed in Figure 3A.
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antibodies directed to KLF4 (Millipore, Billerica, MA); N-cadherin,
Snail, cleaved caspase 3, and cleaved caspase 7 (Cell Signaling, Beverly,
MA); E-cadherin and P120 (BD Transduction Laboratories, Bed-
ford, MA); β-actin (Sigma); and vimentin (Santa Cruz Biotechnology).
Peroxidase-conjugated secondary antibodies were from Santa Cruz
Biotechnology. Blots were developed with Pierce ECL Western Blot-
ting Substrate (Thermo Scientific, Rockford, IL). Bands were quan-
tified using ImageJ software (Rasband, WS, US National Institutes
of Health, Bethesda, MD).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as previ-
ously described [15] or using the human KLF4 ExactaChip (R&D
Systems, Minneapolis, MN) following the manufacturer’s protocol.
Statistical Analyses
Statistical analyses were performed using two-tailed Student’s t test,
unless otherwise stated in figure legends, with P < .05 considered
statistically significant. Error bars represent SDs.
Results
KLF4 Expression Is Inversely Correlated with Metastatic
Progression and Inhibits the Migration and Invasion of
4T1 Tumor Cells
While questions exist regarding the role of KLF4 in breast cancer,
Figure 1A reveals that KLF4 protein expression is greatly reduced in
a variety of breast cancer cell lines, representing many of the breast
cancer subtypes, compared with nontransformedMCF-10A andMCF-
12A mammary epithelial cells. These data further support a recent
report indicating that KLF4 expression is downregulated in primary
human breast tumors compared with normal breast [14]. Previous
work in our laboratory demonstrated that forced expression of KLF4
was able to inhibit migration and invasion of the metastatic MDA-MB-
231 breast cancer cell line [15]; however, the relationship between
KLF4 expression and metastasis remains unclear. We examined
KLF4 expression in two cell line series that have been widely used to
study the molecular events during breast cancer development and
metastasis. The MCF-10A series is composed of at least four isogenic
lines, representing normal breast epithelium (MCF-10A), benign cells
(MCF-10AT1K), carcinoma in situ (MCF-10ACA1h), and invasive
carcinoma (MCF-10ACA1a), the latter of which forms metastases to
the lungs [29,30]. The 4T1 series consists of several lines that were
isolated from a single spontaneously arising BALB/c mouse mammary
tumor [31]. When orthotopically injected into the mammary fat pad,
all lines form primary tumors with different metastatic propensities.
We used the 4T1 line, which is highly metastatic to multiple sites;
the 4T07 line, which forms micrometastases at several sites; and the
67NR line, which is nonmetastatic. To determine whether KLF4 ex-
pression is reduced with increasing metastatic potential, we performed
qRT-PCR of both series. KLF4 expression decreases with increasing
metastatic capacity in the MCF-10A series (Figure 1B). Likewise,
KLF4 is lowest in the most metastatic line of the 4T1 series and is
elevated in the less metastatic sibling lines (Figure 1C). We have pre-
viously shown that loss of KLF4 results in increased migration of
MCF-10A cells [15]. To determine whether KLF4 overexpression
has the opposing effect in the aggressive 4T1 cell line, these cells were
transduced with an adenoviral KLF4 overexpression vector (AdKLF4).
KLF4 overexpresssion caused a significant reduction in both migration
(Figure 1D) and invasion (Figure 1E) when compared with adenovirus
empty vector control (AdGFP) cells. Thus, reduced KLF4 expression
during metastatic progression and the ability of KLF4 to reduce the
migratory and invasive capacities of mammary cancer cells suggest a
role for KLF4 in preventing breast cancer metastasis.
KLF4 Alters the Growth of 4T1 Cells by Inhibiting
Proliferation and Increasing Apoptosis
KLF4 is an established regulator of proliferation through transcrip-
tional control of multiple cell cycle factors [32]. Bright-field micros-
copy revealed decreased cell number in KLF4-overexpressing 4T1
cells when compared with AdGFP-infected controls (data not shown).
Figure 2. KLF4 overexpresssion inhibits growth of 4T1 cells. (A)
Representative density plots from FACS analysis of 4T1 cells in-
fected with either AdGFP or AdKLF4 for 72 hours. Cells in the
upper right quadrant are positive for BrdU incorporation. Cells in
the bottom left quadrant represent cells in the sub-G1 phase. (B)
Quantitation of BrdU incorporation (*P < .02) and (C) sub-G1 pop-
ulation (P = .08). (D) Representative Western blot showing in-
creased levels of cleaved caspase 3 and cleaved caspase 7 in
AdKLF4-4T1 cells compared with AdGFP-4T1 control cells. Experi-
ments were performed at least three times in triplicate.
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FACS analyses of BrdU incorporation were used to determine whether
KLF4 overexpression resulted in decreased proliferation. The per-
centage of BrdU-positive cells was reduced in the AdKLF4-transduced
cells compared with the AdGFP control cells (Figure 2, A and B).
KLF4 also induces apoptosis in a variety of cancer cells including
lymphoma [33], gastric [7], bladder [8], and colon [34] cancer cells.
Hence, we determined whether forced expression of KLF4 also altered
apoptosis in the 4T1 cells. Propidium iodide staining and cell cycle
analysis indicated a trend toward an increase in the sub-G1 population
of the AdKLF4 cells (Figure 2, A and C), suggesting an increase in the
amount of cell death. Western blot analyses further revealed an in-
crease in cleaved caspase 3 and cleaved caspase 7 (Figures 2D and
W1A), indicating that KLF4 does indeed increase apoptosis. These
data demonstrate that, in addition to regulation of metastasis, KLF4
may also affect primary tumor growth of breast cancer cells by decreas-
ing proliferation and increasing apoptosis.
Transient Overexpression of KLF4 Inhibits Primary
Mammary Tumor Growth and Decreases Lung
and Liver Micrometastases
We next evaluated the ability of KLF4 to regulate tumor growth
and progression using a xenograft model and transient overexpression
of KLF4. Orthotopic injection of 4T1 cells into immunocompetent
syngeneic mice, resulting in primary tumor formation and metasta-
ses, is a clinically relevant model of spontaneous breast cancer closely
resembling many of the processes observed in the human disease
[35]. 4T1 cells were transduced with either AdGFP or AdKLF4 and
subsequently injected into the mammary fat pad of 6- to 8-week-old
female BALB/c mice. An aliquot of the transduced cells was also
replated and analyzed for elevated KLF4 expression, which was con-
firmed for up to 7 days after infection (Figure 3A). A 5-day time
course of AdKLF4 protein expression in 4T1 cells is shown in Fig-
ure W1A. As shown in Figure 3B, the growth of primary tumors aris-
ing from AdKLF4-transduced 4T1 cells was reduced at day 13,
compared with control AdGFP-4T1 tumors. In a separate experimen-
tal cohort using luciferase-expressing 4T1 cells (4T1-luc), a similar
reduction in tumor volume was observed in the AdKLF4 group com-
pared with controls (Figure 3C). Neither AdGFP tumors nor AdKLF4
tumors were palpable until at least 8 days after injection; however,
in vivo bioluminescence imaging revealed a decrease in the AdKLF4
tumor size compared with the AdGFP controls at 5 days after injec-
tion (Figure 3, D and E). For mice imaged at 5 days, tumors were
resected from half of the animals in each group, and KLF4 expression
was confirmed in tumor sections using a Flag antibody that recognizes
exogenous, adenovirally expressed, flag-KLF4 (Figure 3F ). Five days
after implantation, the percentage of strongly expressing cells is greatly
reduced compared with postinfection day 1, but similar to the percent-
age seen in day 5 cultures, in vitro (Figure W1, B and C ). Although
KLF4-induced inhibition of growth was detectable at day 5 after
implantation, no differences in proliferation (phospho-Histone H3
staining) or apoptosis (TUNEL staining) were observed at this time
point (data not shown), suggesting that earlier changes in these pro-
cesses must have occurred, which led to reduced tumor size at this later
time point. This possibility is further supported by the greatly reduced
number of cells still expressing KLF4 (Figures 3F and W1, B and C)
and the increased expression of cleaved caspase 3 observed in the
AdKLF4-infected cells compared with the AdGFP-infected controls
at days 2 and 3, in vitro (Figure W1A).
4T1 tumors metastasize to various organs including lung and liver
[31]. Tumor cell dissemination occurs early in this model, and early
resection of primary tumors does not preclude metastatic spread
Figure 3. KLF4 inhibits primary tumor growth of 4T1 cells. (A) Western blot shows maintained (in vitro) expression of virally transduced
KLF4 in 4T1 cells at days 4 and 7 after infection. (B) 4T1 (n = 5 per group) and (C) 4T1-luc (n = 4 per group) tumors expressing AdKLF4
have reduced volume compared with AdGFP control tumors. Tumors were measured using calipers at various intervals during a 2-week
period. (D) AdKLF4 significantly reduces primary tumor formation determined by whole animal bioluminescence scanning at day 5 after
injection (AdGFP, n = 9; AdKLF4, n = 10). Luminescence is expressed as photons/second per region of interest. (E) Bioluminescent
images of three representative animals from each group in D. The relationship between color and light intensity in arbitrary units is given
by the color bar to the right of each group. (F) Immunohistochemical staining of primary AdGFP-4T1 and AdKLF4-4T1 mammary tumors
dissected at day 5 after injection, using anti-flag to detect exogenous KLF4. *P < .01. **P < .005. ***P < 5.0e − 6.
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[36]. On the basis of our migration and invasion studies, we hypoth-
esized that forced expression of KLF4 early during the tumorigenic
process may prevent or delay metastases. To test this, we examined
the lungs and livers from AdGFP control and AdKLF4 tumor-bearing
mice at 21 days after injection. On removal of the lungs, no macro-
metastases were visible from either control or AdKLF4 group. How-
ever, bioluminescence imaging and histologic examination of multiple
lung sections revealed that more than 60% of the mice in the con-
trol AdGFP group, compared with less than 10% of AdKLF4 tu-
mor-bearing mice, had developed lung micrometastases (Table 1
and Figure 4, A1 and A2). To identify tumor cells in the liver, tissue
sections were stained with anti–cytokeratin 5/6 (Figure 4, A3–A6 ) and
quantified. While all mice had developed micrometastases at this
time, AdKLF4 reduced the number of micrometastases in the liver
by 40% (Figure 4B). Hence, transient restoration of KLF4 expression
attenuates early metastatic progression in a clinically relevant mouse
model of breast cancer.
KLF4 Expression Is Suppressed in Two Mouse Models of
HER2/Neu–Positive Breast Cancer
We previously reported transcriptome analyses of MMTV-c-neu
(NeuN)–induced mouse mammary tumors [26]. Further evaluation
of these data revealed a progressive decrease in KLF4 expression with
increasing tumor progression (Figure 5A). Microarray data were fur-
ther confirmed using qRT-PCR (Figure 5B). In addition, we exam-
ined the expression of KLF4 in tumors arising in NeuT mice that
express the activated rat Neu oncogene from the MMTV promoter
[24]. Similar to mice that overexpress the wild-type Neu oncogene
(NeuN), tumors from NeuT mice also displayed a dramatic loss of
KLF4 messenger RNA (mRNA; Figure 5B). To determine whether
enforced expression of KLF4 would alter MMTV-NeuT–induced tu-
mor progression, we generated a tritransgenic model that drives in-
ducible overexpression of KLF4 in the mammary gland (Figure 5C ).
A “tet-ON” transgenic line (MTB) expressing the reverse tetracycline
transactivator (rtTA), under control of the mouse mammary tumor
virus promoter (MMTV-rtTA), has been previously characterized and
shown to express rtTA in the mammary glands of virgin female mice
as early as 5 weeks of age [37]. Mice with a doxycycline-inducible
transgene that expresses KLF4 (TRE-KLF4) [25] were crossed with
the MTB mice to yield the MTB/TRE-KLF4 bitransgenics. In the
presence of doxycycline, these mice displayed elevated KLF4 in the
mammary epithelium compared with control littermates (Figure 5D).
We next crossed control MTB and MTB/TRE-KLF4 mice with ho-
mozygous MMTV-NeuT mice. On weaning, all mice were continu-
ously administered doxycycline in the water for the remainder of the
experiment. As expected, control MTB/NeuT mice developed tumors
with a mean tumor latency of 29 weeks. Surprisingly, forced expres-
sion of KFL4 in the MTB/TRE-KLF4/NeuT tritransgenics did not
significantly alter mammary tumor latency (Figure 5E ). However,
despite increased KLF4 levels in normal mammary epithelium, when
we examined KLF4 mRNA expression in these tumors compared with
the controls, there was no evidence of KLF4 overexpression (Fig-
ure 5F ). These data indicate that KLF4 expression is incompatible
with HER2/Neu tumorigenesis and that cells expressing KLF4 undergo
negative selection during formation of mammary tumors.
KLF4 Inhibits Snail Expression in Both MCF-10A Mammary
Epithelial Cells and 4T1 Breast Cancer Cells
We have previously identified KLF4 as an inhibitor of EMT in
mammary epithelial cells, in part, through activation of E-cadherin
gene expression [15]. In contrast to KLF4, Snail plays an important
role in the induction of EMT through transcriptional suppression of
E-cadherin [19]. Recently, Snail expression was found to be sup-
pressed by KLF4 during the reprogramming of mouse fibroblasts
Table 1. Incidence of Lung and Liver Micrometastases in AdGFP-4T1 and AdKLF4-4T1 Tumor-
Bearing Mice at 21 Days After Injection.
Mice No. of Mice with Micrometastases
Lung Liver
AdGFP (n = 9) 6 9
AdKLF4 (n = 9) 1* 9
*P = .025, Fisher exact test.
Figure 4. KLF4 overexpression decreases lung and liver micro-
metastases. (A1) Representative micrometastasis from lung of
AdGFP-4T1 mouse and (A2) largest metastasis from the only
AdKLF4-4T1 mouse that developed lung metastases. (A3–A6) Rep-
resentative liver sections from AdGFP-4T1 mice and AdKLF4-4T1
mice stained with anti–cytokeratin 5/6 (CK5/6) to detect metastatic
mammary tumor cells in the liver (arrows). (B) Quantitation of CK5/
6 staining. Livers from AdKLF4-4T1 mice had a significant reduc-
tion in micrometastases compared with AdGFP-4T1 mice (Mann-
Whitney test, *P < .05). Both lungs and livers were harvested at
day 21 after injection.
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into induced pluripotent stem (iPS) cells [38]. Therefore, we postu-
lated that, in addition to E-cadherin, Snail may be a target through
which KLF4 inhibits metastasis of breast cancer cells. We first analyzed
Snail expression in 4T1 cells infected with control AdGFP or
AdKLF4. KLF4 overexpression in 4T1 cells decreased both Snail tran-
script and protein (Figure 6, A and B) while at the same time increasing
E-cadherin levels. Decreased Snail protein expression was observed as
early as 1 day after infection with AdKLF4 (Figure 6, C and D). Con-
versely, we found that loss of KLF4 (shKLF4) in the nontransformed
MCF-10A cells in which KLF4 expression has been stably reduced
[15] (Figure 6F) resulted in increased Snail mRNA and protein levels
(Figure 6, E and F), as well as other molecular changes consistent with
EMT, including decreased E-cadherin, a P120 isoform switch, and an
increase in the mesenchymal marker, vimentin, when compared with
the control cells (shNS). To determine whether KLF4 could directly
influence transcription of the SNAI1 gene, we performed ChIP assays
Figure 5. Loss of KLF4 expression in HER2/Neu–induced mouse mammary tumors. (A) Microarray analysis of MMTV-Neu–induced tu-
mors (NeuN) [26] reveals a significant reduction in KLF4 expression when compared with both age-matched wild-type (AMWT) and
hyperplastic tissue. #P < 1.0e − 4. &P < 2.0e − 7. (B) qRT-PCR confirms decreased expression of KLF4 in NeuN tumors compared
with AMWT glands. The reduction in KLF4 expression is comparable between tumors from NeuN mice and tumors from transgenic
mice expressing activated Neu (NeuT). AMWT, n = 3; NeuN, n = 4; NeuT, n = 3. *P < .05. (C) Breeding paradigm used to generate
triple-transgenic mice expressing the mammary-specific, reversible tetracycline transactivator (rtTA) (MTB), activated Neu (NeuT), and
inducible KLF4 (TRE-KLF4). (D) Doxycycline induction of KLF4 in the mammary epithelium of MTB/TRE-KLF4 mice. Both MTB control and
MTB/TRE-KFL4 mice were administered water containing 5% sucrose and 2 mg/ml doxycycline (Sigma) for 3 weeks before tissue har-
vest. Sections were stained with anti-KLF4. (E) NeuT-induced tumor latency is not altered in mice harboring the KLF4 expression cas-
sette. All mice were administered doxycycline starting at weaning, and palpated twice weekly, starting at 15 weeks. MTB/NeuT, n = 16;
MTB/NeuT/TRE-KLF4, n = 14. Statistical analysis and graphical representation of tumor development were generated by Kaplan-Meier
survival analysis. Censored events or animals that were removed for reasons unrelated to tumor development are indicated with an “X.”
Median tumor latencies between groups were not different (log-rank test, χ 2 = 0.05, P= .81). (F) Doxycycline-inducible KLF4 expression
is lost in tumors from the MTB/TRE-KLF4/NeuT mice. qRT-PCR showing comparable levels of KLF4 expression between tumors that
do not carry the inducible KLF4 transgene (MTB/NeuT, n = 7) and those that do (MTB/TRE-KLF4/NeuT, n = 6). P = .98.
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using primers to detect binding at consensus KLF4 binding motifs
identified in the −1500 to +260 bases of the human SNAI1 promoter
(Figure 6G). Direct binding of endogenous KLF4 to site K1 and K2
was detected in MCF-10A cells (Figure 6H ). MDA-MB-231 breast
cancer cells have low levels of endogenous KLF4 (Figure 1A), and
KLF4 binding to the SNAI1 promoter was undetectable in control
AdGFP-infected cells. However, binding of KLF4 to both the K1
and K2 sites in AdKLF4 infected cells was readily detected (Figure 6I ).
These results indicate that one mechanism whereby KLF4 regulates
the migratory and invasive capacity of breast cancer cells and, in turn,
tumor metastasis may be through direct transcriptional suppression of
SNAI1 expression.
Discussion
This study demonstrates that forced expression of KLF4 in the
orthotopic 4T1 model inhibits primary tumor growth and metastases
Figure 6. KLF4 inhibits Snail expression in mammary epithelial cells and tumor cells. (A and B) Forced expression of KLF4 (AdKLF4) in
4T1 cells inhibits Snail while increasing E-cadherin expression. (C) Representative Western blot analysis of Snail expression from day 1
(d1) to day 5 (d5) of adenoviral infection with either AdGFP (G) or AdKLF4 (K). (D) Densitometric quantification of Snail protein levels in
AdGFP- and AdKLF4-infected 4T1 cells. (E) Stable knockdown of KLF4 (shKLF4) in MCF-10A cells results in increased Snail mRNA expres-
sion, compared with control (shNS) cells, as detected by qRT-PCR. (F) Representative Western blot showing increased Snail protein ex-
pression with loss of KLF4. Other changes associated with EMT are also observed such as increased vimentin and loss of E-cadherin. (G)
The human SNAI1 promoter contains two putative KFL4 binding sites as determined using MatInspector. Locations of primers flanking K1
and K2 sites are represented with arrowheads. (H and I) ChIP analysis was performed as indicated in Materials and Methods using MCF-
10A cells or MDA-MB-231 cells infected with AdGFP or AdKLF4. Chromatin was immunoprecipitated with an antibody to KLF4. Immuno-
precipitations with either IgG or anti-KLF4 in AdGFP-infected cells were used as negative controls. The bradykinin 2 receptor (B2R)
promoter was used as a positive control. For RNA and protein, cells were plated in triplicate and harvested at 48 hours after infection
in A and B or at day indicated in C and D. Experiments were performed at least three times. *P < .05. **P < .01. #P < 2.0e − 4.
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of breast cancer cells and that KLF4 expression is lost during HER2/
Neu–induced mammary tumorigenesis. Taken together, these find-
ings provide the first in vivo evidence supporting a role for KLF4
as a tumor and metastases suppressor in the breast. These functional
data are further supported by the ability of KLF4 to inhibit breast
cancer cell proliferation, promote apoptosis, and reduce expression
of the metastasis inducer, Snail.
KLF4 has been recognized as a tumor suppressor in many types of
cancer and, more recently, has been shown to suppress the migration
and invasion of esophageal [39] and breast cancer [15] cells, suggest-
ing its potential role as a metastasis suppressor. However, conflicting
data exist regarding the function of KLF4 in breast cancer. Initial
studies using immunohistochemical and in situ analyses of human
breast tumors reported increased KLF4 expression relative to adja-
cent, uninvolved epithelium [12], whereas subsequent reports have
shown that KLF4 mRNA levels are decreased in breast cancer, rela-
tive to normal tissue, and inversely correlated with increasing tumor
grade [14]. In vitro, the ability of KLF4 to act as tumor suppressor or
tumor promoter has been shown to be largely cell type specific [40],
yet many studies examining the role of KLF4 in breast cancer have
been conducted in fibroblast and other nonmammary epithelial cells.
A recent study examining the role of KLF4 in the generation of iPS
cells from fibroblasts versus epithelial cells [38] highlights the re-
quirement of examining KLF4 in a cell-specific context. Even within
the same breast cancer cell line, it has been reported that loss of
KLF4 induces apoptosis in MCF7 cells [13], whereas others dem-
onstrate that KLF4 inhibits estrogen-dependent proliferation in these
same cells [14]. Recently, it has been reported that silencing of KLF4
in the MDA-MB-231 cells results in inhibition of primary tumor
growth in immunocompromised nonobese diabetic/severe combined
immunodeficiency mice [41]. These findings are in direct contrast
to the reduced tumor volume seen with forced KLF4 expression in
the immunocompetent 4T1 tumor model described here (Figure 4).
Like the 4T1 cells, MDA-MB-231 cells have much lower levels of
KLF4 compared with less aggressive breast cancer cell lines [15,42].
These data suggest that a basal level of KLF4 may be required for cell
growth and survival, and this is consistent with data from MCF-10A
cells where KLF4 suppression causes a decrease in proliferation [15].
Tumorigenic progression is a multistep process. Here we show, in
concordance with human breast cancer arrays, that KLF4 expression
is progressively suppressed in a mouse model of metastatic breast
cancer that is induced by HER2/Neu overexpression (Figure 5A).
Whereas KLF4 overexpression can be seen in the normal mammary
epithelium of the MTB/TRE-KLF4 mice, the inability to exogenously
express KLF4 in the HER2/Neu-induced tumors suggests that KLF4
precludes tumor formation. As the transgenic expression of NEU and
KLF4 is not ubiquitous throughout the normal mammary epithelium,
one possibility is that the cells expressing NEU, and not KLF4, are
those capable of forming tumors. It is also is feasible that HER2/Neu
signaling may posttranscriptionally block KLF4 expression.
Before the study reported herein, little was known regarding the
role of KLF4, if any, during metastatic progression. Recently, Tian
et al. [39] found that KLF4 was suppressed by microRNA (miR)-
10b, resulting in increased migration and invasion of esophageal can-
cer cells. This becomes significant in the context of breast cancer as
Ma et al. [43] have shown that silencing of miR-10b inhibits metas-
tasis of 4T1 mouse tumors. We found that KLF4 expression inhibits
lung and liver micrometastases in this same model (Table 1 and Fig-
ure 5). Other evidence supporting such a role for KLF4 is its ability
to suppress EMT in mammary epithelial cells as well as support the
mesenchymal-to-epithelial transition during iPS cell generation from
fibroblasts [15,38]. Compelling evidence for EMT in breast cancer
and its role in metastasis comes from recent studies examining a tran-
scriptional driver of this process, Snail, and its elevated expression in
carcinomas associated with lymph node metastases, as well as its ex-
pression in distal metastases [21,44,45]. We found that, in addition
to other molecular changes associated with EMT, KLF4 suppresses
Snail expression in both mammary epithelial cells and breast tumor
cells (Figure 6). ChIP analyses indicate that this effect likely occurs
through direct binding and regulation of the SNAI1 gene by KLF4.
The concurrent inhibition of Snail and activation of E-cadherin by
KLF4 suggests that induction of mesenchymal-to-epithelial transi-
tion is one mechanism whereby KLF4 inhibits metastasis. KLF4
and Snail seem to act in a yin-and-yang manner to modulate the
epithelial phenotype. Whereas KLF4 maintains the expression of
a multitude of epithelial-specific genes [32], Snail transcriptionally
suppresses several of the same targets. Of note, KLF4 is also repressed
by Snail [46]. Thus, it seems that a negative feedback loop exists be-
tween these two transcriptional regulators to control the epithelial or
mesenchymal states.
It has been well established that breast cancer is not one, bio-
logically distinct disease, but a heterogeneous group of at least five
different molecular subtypes, each having different outcomes
[47,48]. While our findings begin to shed some light on the function
of KLF4 in breast cancer and metastatic progression using two sep-
arate mouse models of mammary tumorigenesis, it is important that
additional models, both in vitro and in vivo, representing various
breast cancer subtypes be examined. Molecular heterogeneity of
breast cancer could, in part, be explained by the stem cell hypothesis
[49], whereby tumors arise from mammary stem cells that are en-
dowed with multilineage differentiation potential and self-renewal
[50]. As KLF4 plays a role in the induction and maintenance of
iPS cells, it will also be important to determine whether similar reg-
ulation occurs in mammary and tumor stem cells. In summary, loss
of KLF4 during mammary tumorigenesis, in combination with the
ability of KLF4 to reduce tumor formation and metastasis, supports a
tumor and metastasis-suppressive role for KLF4 in breast cancer.
Whereas further studies are required to characterize the reciprocal
regulation between Snail and KLF4, our findings provide new in-
sights into a potential mechanism by which KLF4 inhibits breast
cancer metastasis.
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Supplemental Materials and Methods
Immunocytochemistry
Cells were grown on glass coverslips and fixed in 4% paraformaldehyde
containing 4% sucrose, permeabilized with 0.25% Triton X-100, blocked
with 10%bovine serumalbumin, and incubatedwith anti-FlagM2 (1:500)
for 2 hours at 37°C. After incubationwith Alexa Fluor 594–conjugated sec-
ondary antibody (Invitrogen, Molecular Probes), coverslips were mounted
withVectashield hardestmountingmediumcontainingDAPI (Vector Lab-
oratories, Burlingame, CA) and examined by fluorescence microscopy.
Figure W1. Time course of AdKLF4 overexpression in 4T1 cells. (A) Western blot analysis of AdGFP- (G) and AdKLF4- (K) infected 4T1
cells, in vitro. (B) Immunocytochemical detection of AdKLF4 expression during a 5-day time course in 4T1 cells. KLF4-overexpressing
cells were labeled with anti-Flag (red). Nuclei were counterstained with DAPI (blue). (C) Bar graph representing percent of cells infected
with AdKLF4. An average of two 20× fields/coverslip was counted for each time point. Experiments were performed in duplicate.
